Clinical Report: Mortality Risk Factors in COVID-19-Associated Mucormycosis
Overview
This retrospective cohort study of 81 patients with COVID-19-associated mucormycosis (CAM) identified diabetes mellitus as a common comorbidity and corticosteroid use in most cases. Elevated CRP levels and palatal necrosis were associated with increased mortality, while longer antifungal treatment and posaconazole use correlated with improved survival.
Background
Mucormycosis is a rare but aggressive fungal infection predominantly affecting immunocompromised individuals, including those with uncontrolled diabetes. The COVID-19 pandemic has seen a rise in mucormycosis cases, particularly in patients treated with corticosteroids who experience immune suppression. COVID-19-associated mucormycosis (CAM) presents a significant clinical challenge due to its rapid progression and high fatality rate. Early diagnosis and prompt treatment are critical to improving outcomes.
Data Highlights
Characteristic
Value
Number of patients
81
Male (%)
55.6%
Median age (years)
60.0 (IQR 54.0–67.0)
Diabetes mellitus prevalence
76.5%
Corticosteroid use
90.1%
One-month survival
61.7%
Three-month survival
51.9%
Six- and twelve-month survival
50.6%
CRP association with mortality
P = .001 (increased mortality)
Antifungal treatment duration
P < .001 (reduced mortality)
Palatal necrosis hazard ratio (HR)
2.12 (increased mortality risk)
Posaconazole hazard ratio (HR)
0.16 (reduced mortality risk)
Key Findings
Diabetes mellitus was the most common comorbidity, present in 76.5% of CAM patients.
Corticosteroids were administered in 90.1% of cases, reflecting their widespread use in COVID-19 treatment.
Elevated C-reactive protein (CRP) levels were significantly associated with increased mortality (P = .001).
Longer duration of antifungal therapy correlated with reduced mortality risk (P < .001).
Palatal necrosis was identified as a significant risk factor for mortality (HR: 2.12).
Use of posaconazole was associated with a markedly decreased risk of death (HR: 0.16).
Clinical Implications
Clinicians should maintain a high index of suspicion for mucormycosis in COVID-19 patients, especially those with diabetes and those treated with corticosteroids. Monitoring CRP levels may help identify patients at higher risk of mortality. Early initiation and prolonged antifungal therapy, including posaconazole, are critical to improving survival outcomes. Recognizing signs such as palatal necrosis can aid in risk stratification and prompt aggressive management.
Conclusion
COVID-19-associated mucormycosis carries a high mortality risk, influenced by inflammatory markers and clinical features such as palatal necrosis. Prolonged antifungal treatment and posaconazole use significantly improve survival, underscoring the importance of early diagnosis and tailored therapeutic strategies.
References
Mashhad University of Medical Sciences, 2021 -- Mucormycosis Linked to COVID-19: Analyzing Mortality Risk Factors in a Retrospective Cohort Analysis
